These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 8123408)
1. Effect of renal failure on drug metabolism by the liver. Elston AC; Bayliss MK; Park GR Br J Anaesth; 1993 Aug; 71(2):282-90. PubMed ID: 8123408 [No Abstract] [Full Text] [Related]
2. [Safe drug prescribing for patients with renal failure]. Tanaka A; Shimizu H; Matsuo S Nihon Rinsho; 2007 Oct; 65 Suppl 8():58-66. PubMed ID: 18074518 [No Abstract] [Full Text] [Related]
3. [Guidelines for drug administration for dialysis patients]. Nakamoto M Nihon Rinsho; 2004 Jun; 62 Suppl 6():80-6. PubMed ID: 15250273 [No Abstract] [Full Text] [Related]
4. [Individualization of drug therapy in renal or liver insufficiency]. Martin-Facklam M Ther Umsch; 2000 Sep; 57(9):568-72. PubMed ID: 11036437 [TBL] [Abstract][Full Text] [Related]
5. [Pharmacokinetic drug changes in patients with renal failure]. Karie S; Launay-Vacher V; Kozlovskaia NL; Izzedine H; Deray G; Shilov EM Ter Arkh; 2005; 77(6):78-82. PubMed ID: 16078608 [No Abstract] [Full Text] [Related]
6. Drug administration in patients with renal insufficiency. Minimising renal and extrarenal toxicity. Matzke GR; Frye RF Drug Saf; 1997 Mar; 16(3):205-31. PubMed ID: 9098657 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics of mibefradil in hypertensive patients with varying degrees of renal insufficiency. Welker HA; Weidekamm E; Houwing N; de Chatel R Pharmacology; 1998 Jun; 56(6):297-307. PubMed ID: 9654216 [TBL] [Abstract][Full Text] [Related]
8. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Bergman AJ; Cote J; Yi B; Marbury T; Swan SK; Smith W; Gottesdiener K; Wagner J; Herman GA Diabetes Care; 2007 Jul; 30(7):1862-4. PubMed ID: 17468348 [No Abstract] [Full Text] [Related]
9. Single-dose pharmacokinetic studies of abiraterone acetate in men with hepatic or renal impairment. Marbury T; Lawitz E; Stonerock R; Gonzalez M; Jiao J; Breeding J; Haqq C; Verboven P; Stieltjes H; Yu M; Molina A; Acharya M; Chien C; Tran N J Clin Pharmacol; 2014 Jul; 54(7):732-41. PubMed ID: 24374856 [TBL] [Abstract][Full Text] [Related]
10. Drug development perspective on pharmacokinetic studies of new drugs in patients with renal impairment. Lalonde RL; Wagner JA Clin Pharmacol Ther; 2009 Nov; 86(5):557-61. PubMed ID: 19776736 [TBL] [Abstract][Full Text] [Related]
11. Principles of drug administration in renal insufficiency. Lam YW; Banerji S; Hatfield C; Talbert RL Clin Pharmacokinet; 1997 Jan; 32(1):30-57. PubMed ID: 9012555 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics characterization of liposomal amphotericin B: investigation of clearance process and drug interaction potential. Matsui S; Imai S; Yabuki M; Komuro S Arzneimittelforschung; 2009; 59(9):461-70. PubMed ID: 19856794 [TBL] [Abstract][Full Text] [Related]
14. [Effect of liver diseases on pharmacokinetics of drugs]. Lazowski J; Rewerski W Pol Tyg Lek; 1990 Feb 5-12; 45(6-7):95-9. PubMed ID: 2216955 [No Abstract] [Full Text] [Related]
15. [Renal insufficiency and drug metabolism]. Balant LP Therapie; 1987; 42(4):393-7. PubMed ID: 3686475 [No Abstract] [Full Text] [Related]
16. Protein intake in renal and hepatic disease. Ambühl PM Int J Vitam Nutr Res; 2011 Mar; 81(2-3):162-72. PubMed ID: 22139567 [TBL] [Abstract][Full Text] [Related]